SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Director Daniel Lynch Sells 400 Shares

SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Director Daniel Lynch sold 400 shares of the company’s stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $60.00, for a total value of $24,000.00. Following the completion of the sale, the director now owns 130,544 shares in the company, valued at approximately $7,832,640. This represents a 0.31 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Daniel Lynch also recently made the following trade(s):

• On Monday, February 10th, Daniel Lynch sold 175,000 shares of SpringWorks Therapeutics stock. The shares were sold at an average price of $54.46, for a total transaction of $9,530,500.00.

SpringWorks Therapeutics Stock Down 1.0 %

Shares of NASDAQ SWTX traded down $0.57 during midday trading on Wednesday, hitting $55.73. The stock had a trading volume of 2,528,115 shares, compared to its average volume of 2,646,025. The stock has a 50 day simple moving average of $39.95 and a 200-day simple moving average of $37.18. The company has a market capitalization of $4.15 billion, a PE ratio of -14.36 and a beta of 0.81. SpringWorks Therapeutics, Inc. has a 1 year low of $28.21 and a 1 year high of $60.00.

Analysts Set New Price Targets

A number of research firms have weighed in on SWTX. HC Wainwright reaffirmed a “buy” rating and issued a $74.00 price objective on shares of SpringWorks Therapeutics in a report on Wednesday, February 12th. Guggenheim dropped their price objective on SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, January 8th. Evercore ISI boosted their price objective on SpringWorks Therapeutics from $60.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, February 12th. Finally, Wedbush reissued an “outperform” rating and issued a $77.00 price target on shares of SpringWorks Therapeutics in a research note on Monday, February 10th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, SpringWorks Therapeutics presently has an average rating of “Buy” and an average target price of $70.83.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Alpha DNA Investment Management LLC purchased a new stake in shares of SpringWorks Therapeutics during the third quarter worth $411,000. Ally Bridge Group NY LLC purchased a new stake in SpringWorks Therapeutics during the 3rd quarter valued at about $7,296,000. AMI Asset Management Corp purchased a new stake in SpringWorks Therapeutics during the 4th quarter valued at about $1,438,000. Los Angeles Capital Management LLC lifted its stake in SpringWorks Therapeutics by 238.3% in the 3rd quarter. Los Angeles Capital Management LLC now owns 47,212 shares of the company’s stock worth $1,513,000 after purchasing an additional 33,255 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its holdings in shares of SpringWorks Therapeutics by 13.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 602,227 shares of the company’s stock worth $19,295,000 after purchasing an additional 73,613 shares during the last quarter.

SpringWorks Therapeutics Company Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.